Increasingly, the ‘S’ of ESG – Social Impact – is at the top of the agenda of the pharmaceutical company CEOs and their investors worldwide. We had the pleasure of welcoming key industry leaders and experts for a lively discussion on why and how different stakeholders are driving more access to medicine and what needs to change to increase access in the future:

• Josep Catlla, SVP, Head of Corporate Affairs, Communications and CSR at Sanofi
• Lutz Hegemann, M.D., Ph.D., President, Global Health & Sustainability at Novartis
• Charles Gore, Executive Director at the Medicines Patent Pool
• James Hazel, Ph.D., Research program Manager for the Access to Medicine Index at the Access to Medicine Foundation

The discussion was introduced by Stéphane Bazoche, Partner, Head of the Life Science and Healthcare practice and moderated by Jessica Weddle, Partner Life Science and Healthcare, Head of Strategy, Analytics, M&A.

We would like to once again thank our panelists and all participants for making this event such a fruitful moment.